New radiation schedule tested to improve esophageal cancer treatment
NCT ID NCT06912074
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a shorter, more intense course of radiation (hypofractionated) is safer and more effective than the standard longer course for people with advanced esophageal cancer that cannot be surgically removed. All participants first receive two cycles of chemo-immunotherapy (albumin-bound paclitaxel, cisplatin, and toripalimab). Then they are randomly assigned to one of the two radiation schedules, both given with chemotherapy. The study will track cancer progression, survival, and side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
albumin-bound paclitaxel, cisplatin, toripalimab, and radiation therapy
What this could lead to
If successful, this could identify a more effective radiation schedule that improves cancer control and reduces side effects for people with advanced esophageal cancer.
What could go wrong
This is an early phase 2 trial with only 134 participants, so results may not apply to everyone. The treatments have significant side effects, and the new schedule may not be better than the standard one.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••